Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acorda Therapeutics Inc
NASDAQ ACORQ
Data sourced from
and
and
Acorda Therapeutics Inc Accounts Receivable Turnover Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: -8.83%
Acorda Therapeutics Inc Accounts Receivable Turnover Ratio 1 year YoY Change (%) is -8.83% for the quarter ending March 31, 2024. The accounts receivable turnover ratio measures the efficiency of a company in collecting payments from its customers. It is calculated by dividing the company's revenue by its accounts receivable. This ratio provides insight into how quickly a company collects outstanding funds owed to it. A higher turnover ratio implies that the company efficiently converts credit sales into cash, while a lower ratio may indicate delays in collecting payments or potential issues with credit management. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
-
Acorda Therapeutics Inc Accounts Receivable Turnover Ratio for the quarter ending March 31, 2023 was 2.42.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ACORQ
| CEO | - |
| IPO Date | Feb. 10, 2006 |
| Location | United States |
| Headquarters | 2 Blue Hill Plaza, Pearl River, NY, United States, 10965 |
| Employees | 102 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email